Eline Hermans

Dr. Eline Hermans


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
KBKristian Beran
Kristian Beran
EHEline Hermans
Eline Hermans
René HolmRené Holm
René Holm
KSKia Sepassi
Kia Sepassi
JDJennifer Dressman
Jennifer Dressman
Supersaturation and precipitation within the gastrointestinal tract can influence oral absorption of active pharmaceutical ingredients (APIs). Supersaturation of weakly basic APIs upon transfer from the stomach into the small intestine may enhance their absorption, while salt forms of poorly soluble weak acids may generate supersaturated solutions in both stomach and intestine. Likewise, APIs with solubility-limited absorption may be developed as enabling formulations intended to produce supersaturated solutions of the API in the gut. Integrating the supersaturation/precipitation characteristics of the API into the biopharmaceutical risk classification enables comprehensive mapping of potential developability risks and guides formulation selection towards optimizing oral bioavailability (BA). The refined Developability Classification System (rDCS) provided an approach for this purpose. In this work, the rDCS strategy is revisited and a stratified approach integrating the in vitro supersaturation and precipitation behavior of APIs and their formulations is proposed.

8 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KBKristian Beran
Kristian Beran
EHEline Hermans
Eline Hermans
René HolmRené Holm
René Holm
KSKia Sepassi
Kia Sepassi
JDJennifer Dressman
Jennifer Dressman
Dissolution limitations to oral absorption can occur if the time required for dissolution is longer than the transit time across the small intestine and/or if dissolution is slower than the drug’s permeation through the gut wall. These limitations most often occur for poorly soluble drugs. A standard method for overcoming dissolution issues is to reduce the particle size of the (solid) drug. Building on the refined Developability Classification System (rDCS), this work establishes a novel set of equations with which the appropriate degree of particle size reduction needed to mitigate dissolution limitations to absorption can be calculated. According to the type of data available, the appropriate equation(s) for each situation can be applied. Three case examples are used to illustrate implementation of the equations: voriconazole, lemborexant and istradefylline. Although for voriconazole (rDCS Class I) target radius (rtarget) estimates indicate that particle size reduction is unnecessary, for lemborexant (rDCS Class I) a radius of ≤20 µm would be required to improve absorption. For istradefylline (rDCS Class IIb) the rtarget was approximately 12 µm. Results are commensurate with literature information for these three drugs, signaling that the equations are suitable for application to a wide variety of drug substances.

5 October 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
KBKristian Beran
Kristian Beran
EHEline Hermans
Eline Hermans
René HolmRené Holm
René Holm
KSKia Sepassi
Kia Sepassi
JDJennifer Dressman
Jennifer Dressman
The refined Developability Classification System (rDCS) provides a comprehensive animal-free approach for assessing biopharmaceutical risks associated with developing oral formulations. This work demonstrates practical application of a recently advanced rDCS framework guiding formulation design for six diverse active pharmaceutical ingredients (APIs) and compares rDCS classifications with those of the Biopharmaceutics Classification System (BCS). While the BCS assigns five of the APIs to class II/IV, indicating potentially unfavorable biopharmaceutical attributes, the rDCS provides a more nuanced risk assessment. Both BCS and rDCS assign acetaminophen to class I at therapeutic doses. Voriconazole and lemborexant (both BCS II) are classified in rDCS class I at therapeutic doses, indicating suitability for development as conventional oral formulations. Fedratinib is classified as BCS IV but the rDCS indicates a stratified risk (class I, IIa or IIb), depending on the relevance of supersaturation/precipitation in vivo. Voxelotor and istradefylline (both BCS II) belong to rDCS class IIb, requiring solubility enhancement to achieve adequate oral bioavailability. Comparing the rDCS analysis with literature on development and pharmacokinetics demonstrates that the rDCS reliably supports oral formulation design over a wide range of API characteristics, thus providing a strong foundation for guiding development.

11 January 2024 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
SDShirin Dietrich
Shirin Dietrich
JCJens Ceulemans
Jens Ceulemans
EHEline Hermans
Eline Hermans
TATheodoros Argyropoulos
Theodoros Argyropoulos
KGKonstantinos Goumas
Konstantinos Goumas
Christos ReppasChristos Reppas
Christos Reppas
Information on the conditions under which drugs are transferred from the stomach through the upper small intestine after a high-calorie, high-fat meal is very limited. To simulate the drug presence after disintegration and arrival in the antral region, paracetamol solution and Sporanox® amorphous solid dispersion pellets at two dose levels were administered to the antrum of 8 healthy adults 30 min after administration of a high-calorie, high-fat meal on a crossover basis. The overall median buffer capacity of antral contents was estimated to be 18.0 and 24.0 mmol/ml/ΔpH when titrating with NaOH and HCl, respectively. The corresponding values for the contents of upper the small intestine were 14.0 and 16.8 mmol/ml/ΔpH, respectively. The drug transfer process from the antrum through the upper small intestine occurred with apparent first-order kinetics. The best estimate for the antral emptying half-life was 39min and 45min for paracetamol and itraconazole, respectively, the apparent volume of contents of the upper small intestine was more than double compared with previously reported values in the fasted state, the half-life of drug elimination from the upper small intestine was similar to recent estimates for highly permeable drugs in the fasted state, and the apparent volume of antral contents during the first couple of hours post drug administration was 303mL. Information collected in this study could increase the reliability of in silico and/or in vitro modelling approaches applied in clinical drug development.

26 September 2025 in Science Advances
Verified
Journal Article
Open access
MNMaria C. Novaes-Silva
Maria C. Novaes-Silva
MRMariana Rodríguez-Hakim
Mariana Rodríguez-Hakim
BTBenjamin R. Thompson
Benjamin R. Thompson
NWNorman J. Wagner
Norman J. Wagner
EHEline Hermans
Eline Hermans
JVJan Vermant
Jan Vermant
Pulmonary surfactants reduce the work of breathing, enhance compliance, and prevent alveolar collapse. Yet, their role extends beyond that of a simple surfactant; otherwise, exogenous surfactant therapy would fully restore compliance in acute respiratory distress syndrome (ARDS) by increasing surface concentration alone. Here, we show that interfacial microstructure and mechanics, regulated by spontaneous or ventilator-induced sighs, play a critical role. Using interfacial rheometry and structural analysis, including in situ neutron reflectometry and Raman-based techniques, we find that sighs enrich the air-liquid interface with saturated lipids, triggering structural rearrangements. This periodic “reset” transforms the layer into a mechanically robust, DPPC-rich film, where compressional hardening counteracts tension. These findings highlight the nonequilibrium dynamics of surfactant layers and underscore the importance of interfacial compressive stresses, not just tension, in governing lung mechanics. This mechanism helps sustain low interfacial stress and high compliance, offering mechanistic insight to guide protective ventilation strategies upon lung trauma and possibilities to optimize surfactant-enabled pulmonary treatment.

27 May 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FPFelix Paulus
Felix Paulus
JSJef Stappaerts
Jef Stappaerts
ABAnnette Bauer-Brandl
Annette Bauer-Brandl
DLDirk Lauwers
Dirk Lauwers
LSLiesbet Smet
Liesbet Smet
René HolmRené Holm
René Holm
Background/Objectives: Lipid-based formulations (LBFs) are enabling formulations for poorly water-soluble, mostly lipophilic drugs. In LBFs, the drug is pre-dissolved in the formulation which can consist of lipids, surfactants, and/or cosolvents. In cases where the administration of high amounts of a drug is required, exceeding the drug solubility in the lipidic vehicle at the administration temperature, supersaturated LBFs are an option. The standard method described in the literature for inducing supersaturation in LBFs is to dissolve the drug substance in the lipidic vehicle at an elevated temperature, e.g., at 60 °C, and then subsequently let the formulation cool to ambient temperature before administration (heat-based approach). In this work, an alternative approach to induce supersaturation in LBFs was investigated in order to evaluate if higher drug loads, i.e., the concentration of drug dissolved in the vehicle, could be reached compared to the loading obtainable via heating. Methods: A volatile solvent that is miscible with the lipid matrix and in which the compound has a high solubility is added to the lipid matrix, after which the solvent is evaporated. Both approaches were compared in this work investigating two different LBFs loaded with the BCS-class II drugs celecoxib and fenofibrate. Results: When inducing supersaturation by heat, drug loads of 238% for celecoxib and 278% for fenofibrate could be achieved relative to the solubility at ambient temperature. Using the solvent-based approach, drug loads of up to 475% for celecoxib and 557% for fenofibrate could be prepared in the LBFs using dichloromethane (DCM) as the volatile solvent. However, those highly supersaturated preparations showed suboptimal physical stability and quickly led to precipitation when the LBFs were stored at ambient temperature. In addition, selected formulations were analyzed with GC-headspace to determine the residual DCM after solvent evaporation using a vacuum evaporator. This analysis revealed that the DCM content exceeded regulatory requirements, with up to 21,883 ppm DCM in the formulations. Conclusions: Overall, the relatively high residual DCM concentration and the suboptimal physical stability do not make the approach easily usable for generating supersaturated lipid-based formulations.